• Loading stock data…

MS’s Biotechnology Scores

Last Updated on February 12, 2020 by Chris Stang

Financial Health Score

Our Financial Health Score is designed to specifically measure the financial health of developing biotechnology companies. As we looked around at other scoring systems or ranks, we were constantly confronted with the realization that these scores were not applicable to biotechnology. How and why should the same score be used to assess the financial health of developing mid-cap biotechnology companies as mega-cap technology companies? They should not! This is why we diligently created this proprietary measure of financial health. Our proprietary score incorporates important considerations for clinical stage biotechnology companies such as cash runway, debt, and current cash position, among other inputs relevant to developing biotechnology companies.

Our scale ranges from negative five up to a score of twenty-four. Interpretation is as follows:

  • Score of 15.1 to 24 [A]: These companies are the cream of the crop from a financial standpoint based on our proprietary score. There is a strong financial set-up for these companies to develop their clinical assets.
  • Score of 10.2 to 15 [B]: These companies have very favorable financial scores. There is limited concern from a financial standpoint.
  • Score of 5.1 to 10 [C]: Companies in this tier have an average financial score. Companies are not expected to be as high risk as those with lower scores, but have characteristics that warrant careful evaluation.
  • Score of -5 to 5 [D]: The lowest tier on our financial score. These companies have a concerning financial situation which warrants careful evaluation of risks.

Pipeline Score

Our Pipeline Score objectively measures a biotechnology company’s clinical pipeline. Taking into account the number of candidates, the number of indications, the stage of development, and rights to the candidates in key markets, our score will range from -5 to 24, with a higher score representing a stronger score. Companies with lower scores may be due to a limited number of candidate, limited number of indications, or lack of rights to future revenue generated (licensing deals).

Company TickerCompany NameFinancial ScorePipeline Score
ACST Acasti Pharma 1.38-0.70
ADMA ADMA Biologics3.23-5.00
ADRO Aduro BioTech 10.350.48
ADVM Adverum Biotechnologies 14.86-3.62
ADXS Advaxis 13.12-0.56
AGIO Agios Pharmaceuticals 12.1924.00
ALBO Albireo Pharma 12.485.59
AMRN Amarin Corporation 11.92-5.00
APVO Aptevo Therapeutics 2.32-3.62
ARWR Arrowhead Pharmaceuticals 12.421.61
AVEO AVEO Oncology 6.248.91
AXGT Axovant Gene Therapies 2.672.77
AYTU Aytu Bioscience 5.19^
BCRX BioCryst Pharmaceuticals 4.814.66
BLCM Bellicum Pharmaceuticals 9.041.71
BLUE bluebird bio 13.8510.02
CALA Calithera Biosciences 11.6715.72
CFMS ConforMIS 7.59^
CLDX Celldex Therapeutics 11.791.58
CLLS Cellectis  15.11 0.54
CLVS Clovis Oncology 6.218.36
CPRX Catalyst Pharmaceuticals 12.27-1.89
CRSP Crispr Therapeutics 13.272.21
CTMX CytomX Therapeutics 10.801.65
DMPI DelMar Pharmaceuticals 8.360.43
EDIT Editas Medicine 9.7-2.78
EOLS Evolus 4.5^
EPZM Epizyme 16.5113.72
EXEL Exelixis 12.509.65
EYPT Eyepoint Pharmaceuticals 3.0-0.70
FLXN Flexion Therapeutics 9.363.33
FPRX Five Prime Therapeutics 13.323.81
GALT Galectin Therapeutics 17.633.65
GLMD Galmed Pharmaceuticals 16.76-0.70
IMGN ImmunoGen 13.056.08
IMMU Immunomedics 10.7011.13
INO Inovio Pharmaceuticals 7.17Coming Soon
KALA Kala Pharmaceuticals 11.95-0.82
KRYS Krystal Biotech 18.81 0.08
LCTX Lineage Cell Therapeutics 9.391.30
LJPC La Jolla Pharmaceutical Company 4.87-0.70
MGNX MacroGenics 12.48 13.48
MRNA Moderna 12.5512.43
MRTX Mirati Therapeutics 15.355.74
MTNB Matinas BioPharma 14.602.23
NDRA ENDRA Life Sciences 1.59^
NEO NeoGenomics 11.95^
NGMNGM BiopharmaceuticalsComing Soon1.43
NNVC NanoViricides 6.66-5.00
NVAX Novavax 8.378.99
NK Nantkwest 14.612.28
OCUL Ocular Therapeutix 4.874.70
OVID Ovid Therapeutics 11.314.45
PBYI Puma Biotechnology 11.196.73
PRTK Paratek Pharmaceuticals 9.16 -0.92
PTI Proteostasis Therapeutics 13.683.23
PTLA Portola Pharmaceuticals 5.935.09
RARE Ultragenyx Pharmaceutical 15.962.97
RCKT Rocket Pharmaceuticals 14.010.29
RGNX Regenxbio 16.846.75
SAVA Cassava Sciences 16.98-2.26
SESN Sesen Bio 7.431.48
SGMO Sangamo Therapeutics 10.968.24
TGTX TG Therapeutics 3.0917.57
TRVN Trevena 9.681.30
VBIV VBI Vaccines 5.915.53
VKTX Viking Therapeutics 18.902.79
VSTM Verastem 7.336.60
XLRN Acceleron Pharma 18.322.15
ZYNE Zynerba Pharmaceuticals 16.4814.33

^The pipeline score was developed for assessment of drug candidates and is not applicable to diagnostic, surgical companies, or fully commercialized companies.

%d bloggers like this: